Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

被引:0
作者
Amirhossein Mardi
Anastasia V. Shirokova
Rebar N. Mohammed
Ali Keshavarz
Angelina O. Zekiy
Lakshmi Thangavelu
Talar Ahmad Merza Mohamad
Faroogh Marofi
Navid Shomali
Amir Zamani
Morteza Akbari
机构
[1] Shahid Beheshti University of Medical Sciences,Department of Immunology, School of Medicine
[2] I. M. Sechenov First Moscow State Medical University (Sechenov University),Department of Prosthetic Dentistry
[3] College of Health Science,Medical Laboratory Analysis Department
[4] Cihan University of Sulaimaniya,College of. Veterinary Medicine
[5] University of Sulaimani,Department of Hematology and Blood Banking, School of Allied Medical Sciences
[6] Shahid Beheshti University of Medical Sciences,Department of Pharmacology
[7] Saveetha Dental College,Department of Pharmacology and Toxicology
[8] Saveetha Institute of Medical and Technical Science,Immunology Research Center
[9] Saveetha University,Department of Immunology, Faculty of Medicine
[10] Clinical Pharmacy,Shiraz Transplant Center
[11] Hawler Medical University,Department of Medical Biotechnology, Faculty of Advanced Medical Sciences
[12] College of Pharmacy,undefined
[13] Tabriz University of Medical Sciences,undefined
[14] Tabriz University of Medical Sciences,undefined
[15] Abu Ali Sina Hospital,undefined
[16] Shiraz University of Medical Sciences,undefined
[17] Tabriz University of Medical Sciences,undefined
来源
Cancer Cell International | / 22卷
关键词
Oncolytic virus (OV); Chimeric antigen receptor (CAR) T-cell therapy; Immunogenic cancer cell death (ICD); Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has encountered several challenges due to antigen heterogeneity, suboptimal CAR T-cell trafficking, and the immunosuppressive features of the tumor microenvironment (TME). Oncolytic virotherapy is a novel cancer therapy that employs competent or genetically modified oncolytic viruses (OVs) to preferentially proliferate in tumor cells. OVs in combination with CAR T-cells are promising candidates for overcoming the current drawbacks of CAR T-cell application in tumors through triggering immunogenic cell death (ICD) in cancer cells. ICD is a type of cellular death in which danger-associated molecular patterns (DAMPs) and tumor-specific antigens are released, leading to the stimulation of potent anti-cancer immunity. In the present review, we discuss the biological causes of ICD, different types of ICD, and the synergistic combination of OVs and CAR T-cells to reach potent tumor-specific immunity.
引用
收藏
相关论文
共 1290 条
  • [31] Kroemer G(2011)Non-canonical inflammasome activation targets caspase-11 Nature 479 117-875
  • [32] Deutsch E(2022)Dysregulation of survivin-targeting microRNAs in autoimmune diseases: new perspectives for novel therapies Front Immunol 13 848-5
  • [33] Chargari C(2019)Necroptosis: a crucial pathogenic mediator of human disease JCI insight 4 e128834-3006
  • [34] Galluzzi L(2019)The role of necroptosis in cancer: a double-edged sword? Biochimica et Biophysica Acta (BBA) Rev Cancer 1871 259-111
  • [35] Kroemer G(2019)Complex roles of necroptosis in cancer J Zhejiang Univ Sci B 20 399-61
  • [36] Ye W(2019)The role of necroptosis in cancer biology and therapy Mol Cancer 18 100-195
  • [37] Gunti S(2020)Necroptosis in immuno-oncology and cancer immunotherapy Cells 9 1823-1962
  • [38] Allen CT(2017)Necroptosis in cancer: an angel or a demon? Tumor Biol 39 1010428317711539-286
  • [39] Hong Y(2012)Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 149 1060-978
  • [40] Clavijo PE(2020)Ferroptosis in cancer cell biology Cancers 12 164-842